Showing posts with label Abbott Laboratories. Show all posts
Showing posts with label Abbott Laboratories. Show all posts

Thursday, February 28, 2013

Abbott Labs 2006 HIV Test Insert


A different story than what you’re told by Bono, Oprah and Barack.
First, the tests have no standard for interpreting their meaning.
  • From the paper: “At present there is no recognized standard for establishing the presence or absence of antibodies to HIV-1 and HIV-2 in human blood.”
Translation: They do not predict illness in people who are not already ill, morbidly impoverished, taking Aids drugs or street drugs.
  • “The risk of an *asymptomatic [not chronically ill] person with a repeatedly reactive [positive]serum sample developing AIDS or an AIDS-related condition is not known“
The tests have no specific, inherent meaning, but meaning is assigned to persons who are in the CDC’s ‘risk group’ They must be ‘interpreted’ for risk group, and not applied to the general population.
  • “Clinical studies continue to clarify and refine the interpretation and medical significance of the presence of antibodies to HIV.”
Note the double-speak – “presence of antibodies.” There is “no standard” for determining the “presence or absence” of antibodies in these tests. The statement above is irrelevant, it has no meaning to this standardless test.
  • “AIDS and AIDS-related conditions are clinical syndromes and their diagnosis can only be established clinically. EIA testing [that’s this test] cannot be used to diagnose AIDS, even if the recommended investigation of reactive specimens suggest suggest?] that the antibodies toHIV are present.”
The tests don’t diagnose, the clinician does, based on – not testing positive or negative – but on the CDC’s ‘risk factors,’ like Blackness, poverty, homosexuality.
  • “Sensitivity for HIV-1 antibodies was computed based on the clinical diagnosis of Aids.”
The tests are validated, not by matching the results with actual infection with any particular, identifiable particle – the “standard” that is missing, but
by using them on people, pre-supposed to be ‘at risk’ for ‘Aids’, that is, people pre-diagnosed with clinical “Aids.”
The tests don’t give the diagnosis – the clinician does – no testing needed. The tests are said to work if and only if you are in the group that is pre-supposed to be

Tuesday, January 29, 2013

FDA-APPROVED HIV TESTS pt 9


Calypte HIV-1 Urine EIA
False positive results occur more frequently when testing urine specimens compared to blood specimens... Supplemental testing of repeatedly reactive urine specimens should be performed using only the Cambridge HIV-1 Western Blot Kit before the HIV-1 status of an individual can be determined.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Thursday, January 17, 2013

FDA-APPROVED HIV TESTS pt 7


ARCHITECT HIV Ag/Ab Combo
The ARCHITECT HIV Ag/Ab Combo assay result and supplemental assay results should be interpreted in conjunction with the patient’s clinical presentation, history, and other laboratory results... An individual who has antibodies to HIV is presumed to be infected with the virus... Clinical correlation is indicated with appropriate counseling, medical evaluation... to determine whether a diagnosis of HIV infection is accurate.



All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list


Tuesday, January 15, 2013

FDA-APPROVED HIV TESTS pt 6

Abbott Prism HIV O-Plus
The presence of HIV-1 and/or HIV-2 antibodies is not a diagnosis of AIDS... A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated with appropriate counseling, medical evaluation, and possibly additional testing to decide whether a diagnosis of HIV infection is accurate.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Sunday, January 13, 2013

FDA-APPROVED HIV TESTS pt 8


Bio-Rad Multispot HIV-1/HIV-2 Rapid Test
A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated... to decide whether a diagnosis of HIV infection is accurate.
RECALL 6 June 2008 – The typographical error will be corrected for future shipments of Multispot.
RECALL 13 May 2004 – Software error was contained on the ETI-LAB Applications disk for programming the BioRad HIV-1/HIV-2 Plus O assay. The error induced specimen and conjugate incubation temperatures for the assay to remain at ambient temperature rather than the required 37°C temperature.





All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Saturday, November 17, 2012

Gilead Presents Encouraging Data - HIV therapy Stribild

FOLLOW THE MONEY

Posted
11/16/2012 1:00 PM
 by Zacks Equity Research


Gilead Sciences(GILD) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing phase III studies (102 and 103) as a first-line therapy. Data from study 102 revealed that Stribild was non-inferior to Gilead's Atripla after two years of treatment.

Data from study 103 demonstrated the non inferiority of Stribild to Norvir (ritonavir)-boosted Reyataz plus Truvada after a similar time period. While Norvir is marketed byAbbott Labs(ABT), Reyataz is marketed byBristol-Myers Squibb(BMY). Gilead presented the encouraging results at the 11th international congress on drug therapy regarding HIV infection in the UK.

We note that Stribild, a combination pill, is a new addition to Gilead's formidable HIV franchise. The drug was approved by the US Food and Drug Administration (FDA) in August 2012 as a first-line therapy for treating adults suffering from HIV. The approval was based on encouraging 48 weeks data from studies 102 and 103. Stribild is under review for the same indication in the EU.

Neutral on Gilead

We currently have a Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Holdrating) in the short run. We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the sales ramp of Complera/Eviplera, which together with Stribild, has further fortified the HIV franchise and helped to mitigate the impact of upcoming patent expirations.

Gilead is looking to combat the threat of genericization by inking deals, making acquisitions and introducing new products. To further strengthen its hepatitis C virusportfolio, Gilead purchased Pharmasset earlier in the year, for approximately $11.1 billion.

Friday, January 20, 2012

FDA-APPROVED HIV TESTS pt 5


A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated... to decide whether a diagnosis of HIV infection is accurate.
RECALL 23 Nov 2010 – Reaction Tray lots with ABBOTT PRISM HBsAg and/or ABBOTT PRISM HIV O Plus and to contact ABBOTT for an alternate lot of ABBOTT PRISM Reaction Trays.
RECALL 23 Sep 2010 – Calibration failures when PRISM-HIV-1 Group O Positive Assay Control (2) (Symbol: OPC) is out of specification high.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Thursday, December 29, 2011

FDA-APPROVED HIV TESTS pt 4



It is intended to be used as an aid in the diagnosis and prognosis of patients
with HIV-1 infection.
RECALL 23 Nov 2010 – Reaction Tray lots with ABBOTT PRISM HBsAg and/or ABBOTT PRISM HIV O Plus and to contact ABBOTT for an alternate lot of ABBOTT PRISM Reaction Trays.
RECALL 23 Sep 2010 – Calibration failures when PRISM-HIV-1 Group O Positive Assay Control (2) (Symbol: OPC) is out of specification high.


All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Saturday, December 10, 2011

FDA-APPROVED HIV TESTS pt 3


Abbott HIVAG-1 Monoclonal (1989)
It is intended to be used as an aid in the diagnosis and prognosis of patients with HIV-1 infection.
Device not to be sold or distributed by Abbott after December 6, 1999 in the United States, but are available Internationally. No longer shipped to US customers (2003).
Plasma Donor Screening Recommendations (1995) ... specimens that are repeatedly reactive in the screening assay but which are negative or indeterminate (invalid) by the criteria set forth for neutralization by the manufacturer should be considered INDETERMINATE.
PRE-SUME /prɪˈzum/ verb, - sumed, -sum·ing. verb (used with object) 1. to take for granted, assume, or suppose: I presume you're tired after your drive.
2. Law - to assume as true in the absence of proof to the contrary. 3. to undertake with unwarrantable boldness.
4. to undertake (to do something) without right or permission: to presume to speak for another.
verb (used without object)
5. to take something for granted; suppose. 6. to act or proceed with unwarrantable or impertinent boldness.
7. to go too far in acting unwarrantably or in taking liberties (usually followed by on or upon ): Do not presume upon his tolerance.
Synonyms
presuppose.6. overstep.
1.
... “the usefulness of p24 antigen as a marker of viral load is limited since the antigen is detectable in only 20% of asymptomatic patients...”
... permanent injunction involves the company’s diagnostic devices division... In order to protect the public health, FDA sought action by the Department of Justice.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Sunday, November 27, 2011

FDA-APPROVED HIV TESTS pt 2



A person who has antibodies to HIV-1 is presumed to be infected with the virus... Clinical correlation is indicated... to decide whether a diagnosis of HIV infection is accurate.
RECALL 23 Nov 2010 – Reaction Tray lots with ABBOTT PRISM HBsAg and/or ABBOTT PRISM HIV O Plus and to contact ABBOTT for an alternate lot of ABBOTT PRISM Reaction Trays.
RECALL 23 Sep 2010 – Calibration failures when PRISM-HIV-1 Group O Positive Assay Control (2) (Symbol: OPC) is out of specification high.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Saturday, November 19, 2011

FDA-APPROVED HIV TESTS pt 1


starting a series of posting on ALL the FDA-APPROVED HIV TESTS

1. Abbott HIVABTM HIV-1/HIV-2 (rDNA) EIA

A person who has antibodies to HIV-1 is presumed to be infected with the virus (link to the actual label)... Clinical correlation is indicated with appropriate counseling, medical evaluation and possibly additional testing to decide whether a diagnosis of HIV infection is accurate... AIDS and AIDS-related conditions are clinical syndromes and their diagnosis can only be established clinically... EIA testing cannot be used to diagnose AIDS...”

RECALL 23 Nov 2010 – Reaction Tray lots with ABBOTT PRISM HBsAg and/or ABBOTT PRISM HIV O Plus and to contact ABBOTT for an alternate lot of ABBOTT PRISM Reaction Trays.

RECALL 23 Sep 2010 – Calibration failures when PRISM-HIV-1 Group O Positive Assay Control (2) (Symbol: OPC) is out of specification high.

All the FDA-APPROVED HIV TESTS Here
*credit to omsj.org  for this list

Monday, January 3, 2011

Abbott's HIV drug patent plea rejected for lack of novelty

Business Standard
Tuesday, Jan 04, 2011

BS Reporter / New Delhi January 04, 2011, 1:23 IST
India has rejected an HIV drug patent application filed by US-based Abbott Laboratories, as it lacked “novelty” under domestic laws. The denial of patent will help domestic drug-makers to produce and market low-cost versions of this drug in the developing world.
The rejection of Abbott’s patent application over a combination of lopinavir and ritonavir, sold under the brand name Aluvia, ended the four-year long intellectual property battle between the company and four pre-grant opponents.

In its order on December 30, Mumbai patent office said the drug lacked novelty and did not have any innovative production steps to qualify for patent protection under domestic laws. The Indian Patent Act does not permit patenting of incremental innovations of known substances.

Hailing the verdict, civil society groups said it sets an important precedent to stop pharmaceutical companies from “gaming” the patent system.